Sponsor content
30 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Zirdawny is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ZIRDAWNY donidalorsen (as sodium) 80 mg/0.8 mL solution for injection pre-filled pen.
-
Prescription medicine decision summaryZirdawny has been approved for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
-
Prescription medicine registrationActive ingredients: donidalorsen sodium.
-
Jul-2025Prescription medicine evaluationActive ingredient: donidalorsen.
-
Designation or determinationOrphan drug
-
Cancellation by sponsorRequested by Otsuka Australia Pharmaceutical Pty Ltd
-
Cancellation by sponsorRequested by Otsuka Australia Pharmaceutical Pty Ltd
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Decitabine and cedazuridine
-
Prescription medicine registrationActive ingredients: cedazuridine; decitabine.